Fig. 7

Circulating IGF1 levels and expression of IGF signalling molecules in liver and CL during different treatments. Day12 pregnant rats received oral administration of VEH (2 % ethanol)/AI (1 mg/kg BW), 5 μg (am and pm) E₂ s.c. and 4 mg GH/kg BW (am and pm), s.c. daily for four days. a Upper panel, circulating plasma IGF1 concentrations during different treatments (n = 4 animals/time point). Individual bar represents mean±SEM plasma IGF1 concentrations during different treatments, one-way ANOVA, ^*** P <0.001, ^** P <0.01, ^* P <0.05. a Middle panel, qPCR analysis of Igf1 mRNA. The results are shown as fold changes of mRNA expression during treatments compared to day 16 VEH. Each bar represents mean±SEM, one-way ANOVA, ^*** P <0.001. a Lower panel, a representative immunoblot analysis of IGF1. β-actin was used as loading control for each lane. Each bar represents the fold change with respect to VEH treated liver and indicated as mean±SEM (one-way ANOVA, ^*** P <0.001, ^* P <0.05 n = 4 animals/time point) relative to intensity of β-actin for each treatment. b qPCR fold change expression of Igfbp5, Erα, Igf1 and Igf1r mRNA from different treatment groups. The fold expression change for VEH was set as 1 fold change. Individual bars for each gene represents mean±SEM fold change in mRNA expression for qPCR analysis during different treatments (n = 4, one-way ANOVA, ^*** P <0.001, ^** P <0.01, ^* P <0.05). c A representative immunoblot analysis for IGFBP5 and IGF1 in CL during different treatments. β-actin was used as loading control for each lane. Each bar represents the fold change with respect to VEH treatment and indicated as mean±SEM (n = 4 animals/time point), relative to intensity of β-actin for each treatment (one-way ANOVA, ^*** P <0.001, ^** P <0.01)